Testing for minimal or measurable residual disease (MRD) in blood cancer has transformed the way we look at remission and treatment planning.

In this episode, we speak to Dr. Adriana Rossi of Mt. Sinai Hospital in New York about how MRD testing is being utilized for blood cancer patients. Join us as we explore minimal/measurable residual disease (MRD) testing for blood cancer and its role in guiding treatment decisions and predicting relapse and prognosis.   

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by: Adaptive Biotechnologies

The post Mission To Complete Remission: Utilizing MRD Testing In Blood Cancer first appeared on The Bloodline With Blood Cancer United Podcast.

Have you ever wondered how doctors determine the treatment for a blood cancer patient? In this episode, we’re speaking with Dr. Eric Severson of Labcorp Oncology and Dr. John DiPersio of Washington University in St. Louis, MO, about genomics testing, what it is, and how it benefits blood cancer patients. You will learn about the crucial collaboration between pathologists and oncologists to make sure patients are getting the most accurate diagnosis and best possible treatments for their particular blood cancers.

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by: Labcorp Oncology.

The post The Revolution of Genomics: How Testing Leads to Individualized Treatment first appeared on The Bloodline With Blood Cancer United Podcast.

Join us as we speak to Dr. Lori Muffly and Dr. Matthew Frank from Stanford Medicine in Stanford, CA, about the recent advancements in testing for Minimal/Measurable Residual Disease (MRD). In this episode, we delve into what MRD is, which blood cancers testing is currently used on, and how we can utilize it to more accurately monitor patients and customize treatment. The doctors also share exciting possibilities on how MRD and other testing can benefit patients in the future.

Mentioned

• Minimal/Measurable Residual Disease
• A Medication Resource for Blood Cancer Patients
• Minimal/Measurable Residual Disease Chart 
• Stanford Medicine Research
• CAPP-Seq test – Ash Alizadeh
• Acute Lymphoblastic Leukemia (ALL)  

Additional LLS Support Resources:

• Information Specialists 
• Free telephone/web patient programs 
• Free booklets 
• Financial support 
• Online chats 
• Caregiver support 
• LLS Community 
• Support groups 
• Patti Robinson Kaufmann First Connection Program Free Nutrition Consultations

Support for this episode provided by Genentech, Inc. and Biogen.

The post Exploring Minimal/Measurable Residual Disease (MRD) first appeared on The Bloodline With Blood Cancer United Podcast.